Article Text

Download PDFPDF
Cochrane corner: Positive airway pressure therapy for the treatment of central sleep apnoea associated with heart failure
  1. Shuhei Yamamoto1,
  2. Takayoshi Yamaga2,
  3. Shohei Kawachi3,
  4. Manaka Shibuya4,
  5. Kenichi Nishie5
  1. 1 Department of Rehabilitation, Shinshu University Hospital, Matsumoto, Nagano, Japan
  2. 2 Department of Occupational Therapy, Health Science University, Minamitsuru-gun, Yamanashi, Japan
  3. 3 Department of Biomedical Laboratory Science, Shinshu University Graduate School of Medicine, Matsumoto, Nagano, Japan
  4. 4 Department of Rehabilitation, Kitasato University Hospital, Sagamihara, Kanagawa, Japan
  5. 5 The Department of Respiratory Medicine, Iida Municipal Hospital, Iida, Nagano, Japan
  1. Correspondence to Dr Shuhei Yamamoto, Department of Rehabilitation, Shinshu University Hospital, 3-1-1 Asahi, Matsumoto-shi, Nagano, 390-862, Japan; syamamoto{at}shinshu-u.ac.jp

Statistics from Altmetric.com

Background

This review is a short summary of the Cochrane Review entitled “Positive airway pressure therapy for the treatment of central sleep apnoea associated with heart failure”.1 Heart failure (HF) is the most common cause of death worldwide, and its incidence is rapidly increasing. HF is characterised by symptoms such as fatigue and breathlessness during light activity as well as disordered breathing during sleep. In particular, sleep-disordered breathing (SDB), including central sleep apnoea (CSA) and obstructive sleep apnoea (OSA), is highly prevalent in individuals with chronic HF. Nakamura in his meta-analysis found that adaptive servo-ventilation (ASV) in PAP (positive airway pressure) therapy reduced all-cause mortality (risk ratio (RR) 0.13, 95% CI 0.02 to 0.95) among individuals with HF who had CSA, whereas continuous PAP (CPAP) was not associated with changes in mortality rate.2 However, a recent large trial—the Treatment of Predominant Central Sleep Apnea by Adaptive Servo Ventilation in Patients With Heart Failure (SERVE-HF)—found that ASV including PAP therapy had a higher risk of all-cause mortality and cardiovascular mortality. There was therefore the need for a meta-analysis that included recent trials. The European Society of Cardiology guidelines recommend PAP therapy to improve outcomes caused by SDB, especially OSA for individuals with HF.3 However, ASV in PAP therapy is not recommended for individuals who have HF with reduced ejection fraction (HFrEF) and CSA in light of the results of the SERVE-HF trial.3 4 However, the Study of the Effects of Adaptive Servo-ventilation Therapy on Cardiac Function and Remodeling in Patients with Chronic Heart Failure (SAVIOR-C) trial, which investigated the effects of ASV in HFrEF regardless of SDB in Japan, reported no significant differences in cardiovascular events between ASV and the control group.5 Furthermore, clinical composite response, New York Heart Association (NYHA) classification and symptoms during daily activities …

View Full Text

Footnotes

  • Contributors This editorial was written by SY, TY and KN and based on the systematic review planned, conducted and reported by them and other authors.

  • Funding SY was supported by a grant from the Japan Society for the Promotion of Science (JSPS), KAKENHI (Grant No. JP18K17715), Japan.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.